Dual payload antibody drug conjugates for the treatment
AssigneeAraris Biotech AG
InventorsIsabella ATTINGER-TOLLER, Romain BERTRAND, Rachael FAY, Philipp PROBST, Roger SANTIMARIA, Dragan GRABULOVSKI, Philipp SPYCHER
Life of this patent
Estimating the term…
Abstract
The present invention relates to an antibody-drug conjugate (ADC) comprising as a first payload a cytotoxic molecule and as a second payload a tumor-targeting small molecule for use in the treatment of cancer, wherein the cancer is characterized by the presence of a cancer cell comprising a first antigen that is specifically bound by an antibody portion of the ADC and a second antigen that specifically interacts with the tumor-targeting small molecule.
Claims28
A method of treating cancer in a subject in need thereof, comprising administering to said subject an antibody-drug conjugate (ADC) comprising as a first payload a cytotoxic molecule and as a second payload a tumor-targeting small molecule, wherein the cancer is characterized by the presence of a cancer cell comprising a first antigen that is specifically bound by an antibody portion of the ADC and a second antigen that specifically interacts with the tumor-targeting small molecule.
A method of treating cancer in a subject in need thereof, comprising administering to said subject an antibody-drug conjugate (ADC) comprising as a first payload a cytotoxic molecule and as a second payload a tumor-targeting small molecule, wherein the tumor-targeting small molecule facilitates internalization of the antibody-drug conjugate into a cancer cell comprising an antigen that specifically interacts with the tumor-targeting small molecule and/or improves the killing activity of the antibody-drug conjugate against a cancer cell comprising an antigen that specifically interacts with the tumor-targeting small molecule.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.